Inhibikase Therapeutics (IKT) Net Income towards Common Stockholders (2020 - 2026)
Inhibikase Therapeutics (IKT) posted quarterly Net Income towards Common Stockholders of -$17.8 million for Q1 2026, down 22.21% year-over-year from -$22.9 million in Q1 2025, and up 60.73% quarter-over-quarter from -$45.4 million in Q4 2025.
Inhibikase Therapeutics (IKT) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Net Income towards Common Stockholders for 7 consecutive years, with -$17.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 22.21% year-over-year to -$17.8 million; the TTM figure through Mar 2026 stood at -$86.9 million (down 124.3% YoY), while the FY2025 annual figure was -$83.6 million, down 40.11% from the prior year.
- Net Income towards Common Stockholders advanced to -$17.8 million in Q1 2026 per IKT's latest filing, from -$45.4 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$4.3 million in Q4 2022 and bottomed at -$45.4 million in Q4 2025.
- Historically, Net Income towards Common Stockholders has averaged -$9.9 million across 5 years, with a median of -$5.2 million in 2024.
- Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders rose 16.05% — and 2025, when it tumbled 251.42%.
- Inhibikase Therapeutics' Net Income towards Common Stockholders stood at -$4.3 million in 2022, then declined by 1.58% to -$4.4 million in 2023, then slumped by 193.6% to -$12.9 million in 2024, then sank by 251.42% to -$45.4 million in 2025, then surged by 60.73% to -$17.8 million in 2026.
- Business Quant data shows IKT's Net Income towards Common Stockholders at -$17.8 million in Q1 2026, -$45.4 million in Q4 2025, and -$12.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - | -21.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -21.05 Mn |
| Mar 31, 2026 | -17.84 Mn |
| Dec 31, 2025 | -45.43 Mn |
| Sep 30, 2025 | -12.77 Mn |
| Jun 30, 2025 | -10.87 Mn |
| Mar 31, 2025 | -14.60 Mn |
| Dec 31, 2024 | -12.93 Mn |
| Sep 30, 2024 | -5.98 Mn |
| Jun 30, 2024 | -5.24 Mn |
| Mar 31, 2024 | -4.80 Mn |
| Dec 31, 2023 | -4.40 Mn |
| Sep 30, 2023 | -4.80 Mn |
| Jun 30, 2023 | -6.24 Mn |
| Mar 31, 2023 | -4.76 Mn |
| Dec 31, 2022 | -4.33 Mn |
| Sep 30, 2022 | -4.56 Mn |
| Jun 30, 2022 | -4.64 Mn |
| Mar 31, 2022 | -4.64 Mn |
| Dec 31, 2021 | -5.02 Mn |
| Sep 30, 2021 | -4.47 Mn |